ArticleGenome medicine2026
Proteomic landscape analysis of undifferentiated pleomorphic sarcoma.
Article in Genome medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundProteins represent the dynamic downstream products of genes, and have the potential to substantially increase understanding of the complexities of cancer biology. Undifferentiated pleomorphic sarcoma (UPS) is a rare disease, the proteomic landscape of which has not been fully investigated.
methodsWe performed isobaric TMT-based proteomic analysis for 80 UPS tumor and 28 corresponding adjacent non-tumor muscle tissues. The underlying molecular subtypes, therapeutic targets, local recurrence, and lung metastasis were uncovered. The integration of previous single-cell RNA sequencing data with proteomics was further employed to characterize the specific cell type linked to lung metastasis.
resultsOur analyses revealed a catalog of proteins that were dysregulated in UPS. The UPS cohort was stratified into three molecular subtypes S-I, S-II, and S-III. S-I was characterized by the high expression of spliceosome-related proteins and protumor cytokines, and was associated with the lowest overall rate of survival. S-II was characterized with the highest ImmuneScore. S-III with the highest StromaScore had the best outcomes. Protein-based disease classification was better than the recommended AJCC staging system for UPS. PRMT6 protein was overexpressed, and associated with adverse outcomes. PRMT6 inhibitor significantly inhibited tumor growth in two patient-derived xenograft models. Analysis of local recurrence-associated proteins showed that PAWR was negatively associated with UPS recurrence. Additionally, CD163 was a negative predictive marker for lung metastasis. Combined with scRNA-seq data, CD163 + macrophages represented phagocytosis phenotype with high expression of the signature markers (CD163, MRC1, MERTK, and C1QB). Furthermore, CD163 + macrophages were enriched in the endocytosis, phagocytosis, and lysosome compared with CD163- macrophages.
conclusionsOur study highlights the utility of proteomics for characterizing UPS, providing a framework for understanding the biological basis of its clinical features and paving the way for a new era of proteomics-driven precision medicine in sarcoma research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.